---
document_datetime: 2026-01-19 14:45:00
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/teduglutide-viatris.html
document_name: teduglutide-viatris.html
version: success
processing_time: 0.0992179
conversion_datetime: 2026-01-20 20:24:02.75388
docling_version:
  docling-serve: 1.10.0
  docling-jobkit: 1.8.1
  docling: 2.69.0
  docling-core: 2.60.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.3
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Search

- [Medicines](/en/medicines)
    - [Find medicine](/en/medicines)
    - [Therapeutic areas: latest updates](/en/medicines/therapeutic-areas-latest-updates)
    - [Download medicine data](/en/medicines/download-medicine-data)
    - [What we publish on medicines and when](/en/medicines/what-we-publish-medicines-when)
    - [Medicines under evaluation](/en/medicines/medicines-human-use-under-evaluation)
    - [National registers](/en/medicines/national-registers-authorised-medicines)
- [Human regulatory](/en/human-regulatory-overview)
    - [Overview](/en/human-regulatory-overview)
    - [Research and development](/en/human-regulatory-overview/research-development)
    - [Marketing authorisation](/en/human-regulatory-overview/marketing-authorisation)
    - [Post-authorisation](/en/human-regulatory-overview/post-authorisation)
    - [Medical devices](/en/human-regulatory-overview/medical-devices)
    - [Herbal products](/en/human-regulatory-overview/herbal-medicinal-products)
- [Veterinary regulatory](/en/veterinary-regulatory-overview)
    - [Overview](/en/veterinary-regulatory-overview)
    - [Research and development](/en/veterinary-regulatory-overview/research-development-veterinary-medicines)
    - [Marketing authorisation](/en/veterinary-regulatory-overview/marketing-authorisation-veterinary-medicines)
    - [Post-authorisation](/en/veterinary-regulatory-overview/post-authorisation-veterinary-medicines)
- [Committees](/en/committees)
    - [Overview](/en/committees)
    - [How the committees work](/en/committees/how-committees-work)
    - [CHMP](/en/committees/committee-medicinal-products-human-use-chmp)
    - [CVMP](/en/committees/committee-veterinary-medicinal-products-cvmp)
    - [PRAC](/en/committees/pharmacovigilance-risk-assessment-committee-prac)
    - [COMP](/en/committees/committee-orphan-medicinal-products-comp)
    - [HMPC](/en/committees/committee-herbal-medicinal-products-hmpc)
    - [CAT](/en/committees/committee-advanced-therapies-cat)
    - [PDCO](/en/committees/paediatric-committee-pdco)
    - [Working parties and other groups](/en/committees/working-parties-other-groups)
- [News &amp; events](/en/news-events)
    - [Overview](/en/news-events)
    - [News](/en/news)
    - [Events](/en/events/upcoming-events)
    - [What's new](/en/news-events/whats-new)
    - [Committee highlights](/en/news-events/committee-highlights)
    - [Publications](/en/news-and-events/publications)
    - [Press and social media](/en/news-events/press-social-media)
    - [Podcast: Inside EMA](/en/news-events/podcast-inside-ema)
    - [Open consultations](/en/news-events/open-consultations)
    - [RSS feeds](/en/news-events/rss-feeds)
- [Partners &amp; networks](/en/partners-networks)
    - [Overview](/en/partners-networks)
    - [Animal health practitioners](/en/partners-networks/animal-health-practitioners)
    - [One Health approach](/en/partners-networks/one-health-approach)
    - [Academia](/en/partners-networks/academia)
    - [EU partners](/en/partners-networks/eu-partners)
    - [International activities](/en/partners-networks/international-activities)
    - [Patients and consumers](/en/partners-networks/patients-consumers)
    - [Healthcare professionals](/en/partners-networks/healthcare-professionals)
    - [Pharmaceutical industry](/en/partners-networks/pharmaceutical-industry)
    - [Networks](/en/partners-networks/networks)
    - [Health technology assessment bodies](/en/partners-networks/health-technology-assessment-bodies)
- [About us](/en/about-us)
    - [Overview](/en/about-us)
    - [What we do](/en/about-us/what-we-do)
    - [Who we are](/en/about-us/who-we-are)
    - [How we work](/en/about-us/how-we-work)
    - [Fees](/en/about-us/fees-payable-european-medicines-agency)
    - [Support to SMEs](/en/about-us/support-smes)
    - [Annual reports and work programmes](/en/about-us/annual-reports-work-programmes)
    - [History of EMA](/en/about-us/history-ema)
    - [Careers](/en/about-us/careers)
    - [Procurement](/en/about-us/procurement-grants)
    - [Glossaries](/en/about-us/glossaries)
    - [About this website](/en/about-us/about-website)
    - [Data protection and privacy](/en/about-us/data-protection-privacy-ema)
    - [Contacts](/en/about-us/contacts-european-medicines-agency)

1. [Home](/en/homepage)
2. [Medicines](https://www.ema.europa.eu/en/medicines)
3. Teduglutide Viatris

# Teduglutide Viatris

[RSS](/en/individual-human-medicine.xml/270330)

##### Authorised

This medicine is authorised for use in the European Union

teduglutide Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Teduglutide Viatris](#news-on)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Teduglutide Viatris is a medicine for treating short bowel syndrome (or short gut) in adults and children aged 4 months and above.

Short bowel syndrome is a condition in which nutrients and fluids are not properly absorbed by the gut, usually because a large part of the intestine has been surgically removed.

Teduglutide Viatris contains the active substance teduglutide and is a 'generic medicine'. This means that Teduglutide Viatris contains the same active substance and works in the same way as a 'reference medicine' already authorised in the EU. The reference medicine for Teduglutide Viatris is Revestive. For more information on generic medicines, see the question-and-answer document [here](https://www.ema.europa.eu/en/documents/other/questions-and-answers-generic-medicines_en.pdf) .

Expand section

Collapse section

## How is Teduglutide Viatris used?

The medicine can only be obtained with a prescription, and treatment should be started under the supervision of a doctor with experience in treating short bowel syndrome.

Teduglutide Viatris is given once a day as an injection under the skin of the abdomen (belly). Patients or their carers can inject the medicines once they have received adequate training. Treatment should be stopped if a benefit is not observed.

For more information about using Teduglutide Viatris, see the package leaflet or contact your doctor or pharmacist.

## How does Teduglutide Viatris work?

The active substance in Teduglutide Viatris, teduglutide, is similar to human glucagon-like peptide 2 (GLP 2), a hormone made in the gut that increases absorption of nutrients from the intestine.

Teduglutide works in a similar way to GLP-2 and increases intestinal absorption by increasing blood flow to and from the gut, reducing the speed at which food passes through the intestine and reducing acid secretions in the stomach which can interfere with absorption. Teduglutide has the advantage of lasting longer than GLP-2 in the body.

## How has Teduglutide Viatris been studied?

Studies on the benefits and risks of the active substance in the authorised use have already been carried out with the reference medicine, Revestive, and do not need to be repeated for Teduglutide Viatris.

As for every medicine, the company provided studies on the quality of Teduglutide Viatris. There was no need for 'bioequivalence' studies to investigate whether Teduglutide Viatris is absorbed similarly to the reference medicine to produce the same level of the active substance in the blood. This is because the composition of Teduglutide Viatris is very similar to the reference medicine and, when given by injection under the skin, the active substance in both products is expected to be absorbed in the same way.

## What are the benefits and risks of Teduglutide Viatris?

Because Teduglutide Viatris is a generic medicine, its benefits and risks are taken as being the same as the reference medicine's.

## Why is Teduglutide Viatris authorised in the EU?

The European Medicines Agency concluded that, in accordance with EU requirements, Teduglutide Viatris has been shown to be comparable to Revestive. Therefore, the Agency's view was that, as for Revestive, the benefits of Teduglutide Viatris outweigh the identified risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Teduglutide Viatris?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Teduglutide Viatris have been included in the summary of product characteristics and the package leaflet. Any additional measures in place for Revestive also apply to Teduglutide Viatris where appropriate.

As for all medicines, data on the use of Teduglutide Viatris are continuously monitored. Suspected side effects reported with Teduglutide Viatris are carefully evaluated and any necessary action taken to protect patients.

## Other information about Teduglutide Viatris

Teduglutide Viatris received a marketing authorisation valid throughout the EU on 08 January 2026.

Teduglutide Viatris : EPAR - Medicine overview

Reference Number: EMA/372697/2025

English (EN) (147.85 KB - PDF)

**First published:** 19/01/2026

[View](/en/documents/overview/teduglutide-viatris-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-559)

български (BG) (168.87 KB - PDF)

**First published:**

19/01/2026

[View](/bg/documents/overview/teduglutide-viatris-epar-medicine-overview_bg.pdf)

español (ES) (147.02 KB - PDF)

**First published:**

19/01/2026

[View](/es/documents/overview/teduglutide-viatris-epar-medicine-overview_es.pdf)

čeština (CS) (167.34 KB - PDF)

**First published:**

19/01/2026

[View](/cs/documents/overview/teduglutide-viatris-epar-medicine-overview_cs.pdf)

dansk (DA) (146.99 KB - PDF)

**First published:**

19/01/2026

[View](/da/documents/overview/teduglutide-viatris-epar-medicine-overview_da.pdf)

Deutsch (DE) (149.89 KB - PDF)

**First published:**

19/01/2026

[View](/de/documents/overview/teduglutide-viatris-epar-medicine-overview_de.pdf)

eesti keel (ET) (144.36 KB - PDF)

**First published:**

19/01/2026

[View](/et/documents/overview/teduglutide-viatris-epar-medicine-overview_et.pdf)

ελληνικά (EL) (172.38 KB - PDF)

**First published:**

19/01/2026

[View](/el/documents/overview/teduglutide-viatris-epar-medicine-overview_el.pdf)

français (FR) (150.38 KB - PDF)

**First published:**

19/01/2026

[View](/fr/documents/overview/teduglutide-viatris-epar-medicine-overview_fr.pdf)

hrvatski (HR) (194.25 KB - PDF)

**First published:**

19/01/2026

[View](/hr/documents/overview/teduglutide-viatris-epar-medicine-overview_hr.pdf)

italiano (IT) (145.6 KB - PDF)

**First published:**

19/01/2026

[View](/it/documents/overview/teduglutide-viatris-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (183.3 KB - PDF)

**First published:**

19/01/2026

[View](/lv/documents/overview/teduglutide-viatris-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (166.3 KB - PDF)

**First published:**

19/01/2026

[View](/lt/documents/overview/teduglutide-viatris-epar-medicine-overview_lt.pdf)

magyar (HU) (169.04 KB - PDF)

**First published:**

19/01/2026

[View](/hu/documents/overview/teduglutide-viatris-epar-medicine-overview_hu.pdf)

Malti (MT) (168.92 KB - PDF)

**First published:**

19/01/2026

[View](/mt/documents/overview/teduglutide-viatris-epar-medicine-overview_mt.pdf)

Nederlands (NL) (147.32 KB - PDF)

**First published:**

19/01/2026

[View](/nl/documents/overview/teduglutide-viatris-epar-medicine-overview_nl.pdf)

polski (PL) (171.64 KB - PDF)

**First published:**

19/01/2026

[View](/pl/documents/overview/teduglutide-viatris-epar-medicine-overview_pl.pdf)

português (PT) (147.42 KB - PDF)

**First published:**

19/01/2026

[View](/pt/documents/overview/teduglutide-viatris-epar-medicine-overview_pt.pdf)

română (RO) (163.43 KB - PDF)

**First published:**

19/01/2026

[View](/ro/documents/overview/teduglutide-viatris-epar-medicine-overview_ro.pdf)

slovenčina (SK) (167.79 KB - PDF)

**First published:**

19/01/2026

[View](/sk/documents/overview/teduglutide-viatris-epar-medicine-overview_sk.pdf)

slovenščina (SL) (193.86 KB - PDF)

**First published:**

19/01/2026

[View](/sl/documents/overview/teduglutide-viatris-epar-medicine-overview_sl.pdf)

Suomi (FI) (144.56 KB - PDF)

**First published:**

19/01/2026

[View](/fi/documents/overview/teduglutide-viatris-epar-medicine-overview_fi.pdf)

svenska (SV) (145.19 KB - PDF)

**First published:**

19/01/2026

[View](/sv/documents/overview/teduglutide-viatris-epar-medicine-overview_sv.pdf)

Teduglutide Viatris : EPAR - Risk management plan

English (EN) (773.31 KB - PDF)

**First published:** 19/01/2026

[View](/en/documents/rmp/teduglutide-viatris-epar-risk-management-plan_en.pdf)

## Product information

Teduglutide Viatris : EPAR - Product information

English (EN) (856.56 KB - PDF)

**First published:** 19/01/2026

[View](/en/documents/product-information/teduglutide-viatris-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-711)

български (BG) (1.18 MB - PDF)

**First published:**

19/01/2026

[View](/bg/documents/product-information/teduglutide-viatris-epar-product-information_bg.pdf)

español (ES) (986.26 KB - PDF)

**First published:**

19/01/2026

[View](/es/documents/product-information/teduglutide-viatris-epar-product-information_es.pdf)

čeština (CS) (1.04 MB - PDF)

**First published:**

19/01/2026

[View](/cs/documents/product-information/teduglutide-viatris-epar-product-information_cs.pdf)

dansk (DA) (1.08 MB - PDF)

**First published:**

19/01/2026

[View](/da/documents/product-information/teduglutide-viatris-epar-product-information_da.pdf)

Deutsch (DE) (1.07 MB - PDF)

**First published:**

19/01/2026

[View](/de/documents/product-information/teduglutide-viatris-epar-product-information_de.pdf)

eesti keel (ET) (1 MB - PDF)

**First published:**

19/01/2026

[View](/et/documents/product-information/teduglutide-viatris-epar-product-information_et.pdf)

ελληνικά (EL) (1.13 MB - PDF)

**First published:**

19/01/2026

[View](/el/documents/product-information/teduglutide-viatris-epar-product-information_el.pdf)

français (FR) (1011.01 KB - PDF)

**First published:**

19/01/2026

[View](/fr/documents/product-information/teduglutide-viatris-epar-product-information_fr.pdf)

hrvatski (HR) (1013.99 KB - PDF)

**First published:**

19/01/2026

[View](/hr/documents/product-information/teduglutide-viatris-epar-product-information_hr.pdf)

íslenska (IS) (1.07 MB - PDF)

**First published:**

19/01/2026

[View](/is/documents/product-information/teduglutide-viatris-epar-product-information_is.pdf)

italiano (IT) (987.12 KB - PDF)

**First published:**

19/01/2026

[View](/it/documents/product-information/teduglutide-viatris-epar-product-information_it.pdf)

latviešu valoda (LV) (1.05 MB - PDF)

**First published:**

19/01/2026

[View](/lv/documents/product-information/teduglutide-viatris-epar-product-information_lv.pdf)

lietuvių kalba (LT) (1.06 MB - PDF)

**First published:**

19/01/2026

[View](/lt/documents/product-information/teduglutide-viatris-epar-product-information_lt.pdf)

magyar (HU) (1.04 MB - PDF)

**First published:**

19/01/2026

[View](/hu/documents/product-information/teduglutide-viatris-epar-product-information_hu.pdf)

Malti (MT) (1.09 MB - PDF)

**First published:**

19/01/2026

[View](/mt/documents/product-information/teduglutide-viatris-epar-product-information_mt.pdf)

Nederlands (NL) (951.82 KB - PDF)

**First published:**

19/01/2026

[View](/nl/documents/product-information/teduglutide-viatris-epar-product-information_nl.pdf)

norsk (NO) (1.09 MB - PDF)

**First published:**

19/01/2026

[View](/no/documents/product-information/teduglutide-viatris-epar-product-information_no.pdf)

polski (PL) (1003.01 KB - PDF)

**First published:**

19/01/2026

[View](/pl/documents/product-information/teduglutide-viatris-epar-product-information_pl.pdf)

português (PT) (964.98 KB - PDF)

**First published:**

19/01/2026

[View](/pt/documents/product-information/teduglutide-viatris-epar-product-information_pt.pdf)

română (RO) (1012.75 KB - PDF)

**First published:**

19/01/2026

[View](/ro/documents/product-information/teduglutide-viatris-epar-product-information_ro.pdf)

slovenčina (SK) (1.04 MB - PDF)

**First published:**

19/01/2026

[View](/sk/documents/product-information/teduglutide-viatris-epar-product-information_sk.pdf)

slovenščina (SL) (986.94 KB - PDF)

**First published:**

19/01/2026

[View](/sl/documents/product-information/teduglutide-viatris-epar-product-information_sl.pdf)

Suomi (FI) (1 MB - PDF)

**First published:**

19/01/2026

[View](/fi/documents/product-information/teduglutide-viatris-epar-product-information_fi.pdf)

svenska (SV) (916.17 KB - PDF)

**First published:**

19/01/2026

[View](/sv/documents/product-information/teduglutide-viatris-epar-product-information_sv.pdf)

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Teduglutide Viatris : EPAR - All authorised presentations

English (EN) (45.74 KB - PDF)

**First published:** 19/01/2026

[View](/en/documents/all-authorised-presentations/teduglutide-viatris-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-909)

български (BG) (49.48 KB - PDF)

**First published:**

19/01/2026

[View](/bg/documents/all-authorised-presentations/teduglutide-viatris-epar-all-authorised-presentations_bg.pdf)

español (ES) (40.37 KB - PDF)

**First published:**

19/01/2026

[View](/es/documents/all-authorised-presentations/teduglutide-viatris-epar-all-authorised-presentations_es.pdf)

čeština (CS) (60.23 KB - PDF)

**First published:**

19/01/2026

[View](/cs/documents/all-authorised-presentations/teduglutide-viatris-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (41.85 KB - PDF)

**First published:**

19/01/2026

[View](/da/documents/all-authorised-presentations/teduglutide-viatris-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (43.19 KB - PDF)

**First published:**

19/01/2026

[View](/de/documents/all-authorised-presentations/teduglutide-viatris-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (39.36 KB - PDF)

**First published:**

19/01/2026

[View](/et/documents/all-authorised-presentations/teduglutide-viatris-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (45.3 KB - PDF)

**First published:**

19/01/2026

[View](/el/documents/all-authorised-presentations/teduglutide-viatris-epar-all-authorised-presentations_el.pdf)

français (FR) (39.95 KB - PDF)

**First published:**

19/01/2026

[View](/fr/documents/all-authorised-presentations/teduglutide-viatris-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (58.06 KB - PDF)

**First published:**

19/01/2026

[View](/hr/documents/all-authorised-presentations/teduglutide-viatris-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (40.76 KB - PDF)

**First published:**

19/01/2026

[View](/is/documents/all-authorised-presentations/teduglutide-viatris-epar-all-authorised-presentations_is.pdf)

italiano (IT) (48.51 KB - PDF)

**First published:**

19/01/2026

[View](/it/documents/all-authorised-presentations/teduglutide-viatris-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (59.91 KB - PDF)

**First published:**

19/01/2026

[View](/lv/documents/all-authorised-presentations/teduglutide-viatris-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (57.69 KB - PDF)

**First published:**

19/01/2026

[View](/lt/documents/all-authorised-presentations/teduglutide-viatris-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (60.07 KB - PDF)

**First published:**

19/01/2026

[View](/hu/documents/all-authorised-presentations/teduglutide-viatris-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (58.98 KB - PDF)

**First published:**

19/01/2026

[View](/mt/documents/all-authorised-presentations/teduglutide-viatris-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (40.34 KB - PDF)

**First published:**

19/01/2026

[View](/nl/documents/all-authorised-presentations/teduglutide-viatris-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (43.07 KB - PDF)

**First published:**

19/01/2026

[View](/no/documents/all-authorised-presentations/teduglutide-viatris-epar-all-authorised-presentations_no.pdf)

polski (PL) (61.96 KB - PDF)

**First published:**

19/01/2026

[View](/pl/documents/all-authorised-presentations/teduglutide-viatris-epar-all-authorised-presentations_pl.pdf)

português (PT) (41.01 KB - PDF)

**First published:**

19/01/2026

[View](/pt/documents/all-authorised-presentations/teduglutide-viatris-epar-all-authorised-presentations_pt.pdf)

română (RO) (50.48 KB - PDF)

**First published:**

19/01/2026

[View](/ro/documents/all-authorised-presentations/teduglutide-viatris-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (45.73 KB - PDF)

**First published:**

19/01/2026

[View](/sk/documents/all-authorised-presentations/teduglutide-viatris-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (48.91 KB - PDF)

**First published:**

19/01/2026

[View](/sl/documents/all-authorised-presentations/teduglutide-viatris-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (37.1 KB - PDF)

**First published:**

19/01/2026

[View](/fi/documents/all-authorised-presentations/teduglutide-viatris-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (41.73 KB - PDF)

**First published:**

19/01/2026

[View](/sv/documents/all-authorised-presentations/teduglutide-viatris-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Teduglutide Viatris Active substance teduglutide International non-proprietary name (INN) or common name teduglutide Therapeutic area (MeSH) Short Bowel Syndrome Anatomical therapeutic chemical (ATC) code A16AX08

### Pharmacotherapeutic group

Other alimentary tract and metabolism products

### Therapeutic indication

Teduglutide Viatris is indicated for the treatment of patients 4 months corrected gestational age and above with Short Bowel Syndrome (SBS). Patients should be stable following a period of intestinal adaptation after surgery.

## Authorisation details

EMA product number EMEA/H/C/006564

Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see [Generic and hybrid medicines](/node/69107) .

Marketing authorisation holder

Viatris Limited

Damastown Industrial Park Mulhuddart Dublin Dublin 15 Ireland

Opinion adopted 13/11/2025 Marketing authorisation issued 08/01/2026

## Assessment history

## Initial marketing authorisation documents

Teduglutide Viatris : EPAR - Public assessment report

Adopted

Reference Number: EMA/382685/2025

English (EN) (455.23 KB - PDF)

**First published:** 19/01/2026

[View](/en/documents/assessment-report/teduglutide-viatris-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Teduglutide Viatris

Adopted

Reference Number: EMA/358510/2025

English (EN) (153.18 KB - PDF)

**First published:** 14/11/2025

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-teduglutide-viatris_en.pdf)

#### News on Teduglutide Viatris

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 10-13 November 2025](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-10-13-november-2025) 14/11/2025

**This page was last updated on** 19/01/2026

## Share this page

[Back to top](#main-content)